New heart pump device aims to make risky procedures safer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

To be eligible, subjects must meet ALL of the following inclusion criteria: 1. Age ≥ 18 and ≤ 90 years 2. Will undergo elective or urgent HRPCI, where hemodynamic support is needed, as determined by the institutional Heart Team 3. Signed the informed consent To be eligible, subjects must NOT meet ANY of the following exclusion criteria: 1. Cardiogenic shock or acutely decompensated pre-existing chronic heart failure. Cardiogenic shock is defined as: systemic hypotension (systolic BP \< 90 mmHg or the need for inotropes/pressors to maintain a systolic BP \> 90 mmHg) plus one of the following: any requirement for inotropes/pressors prior to arrival at the catheterization laboratory, clinical evidence of end-organ hypoperfusion or use of intra-aortic balloon pump (IABP), or any other circulatory support device. 2. Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit 3. Evidence of left ventricular thrombus 4. Moderate or greater aortic valvular disease or regurgitation (≥ 2+ on a 4-grade scale as assessed on transthoracic echo cardiogram (TTE) 5. Moderate or greater aortic stenosis (gradient \>20 mmHg or valve area \< 1.5 cm\^2 as assessed on TTE) 6. Previous aortic valve replacement or reconstruction 7. Ascending or descending aortic dissection or aortic aneurysm \> 4.5 cm 8. Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the device 9. Presence of decompensated liver disease; severe liver dysfunction (Child class C) 10. Patients requiring renal replacement therapy with dialysis 11. Infection of the proposed procedural access site or systemic active infection requiring ongoing antibiotic therapy 12. Current or history of heparin-induced thrombocytopenia (HIT) 13. Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or has known hypersensitivity to heparin, aspirin, ADP receptor inhibitors, or nitinol 14. Known or suspected coagulopathy or abnormal coagulation parameters (defined as platelet count ≤ 100,000/mm³ or spontaneous INR ≥ 1.5 or known fibrinogen ≤ 1.5 g/L) 15. Any condition or scheduled surgery that will require discontinuation of antiplatelet and/or anticoagulant therapy within 90 days of the index procedure 16. Planned coronary intervention within 30 days post index procedure 17. Breastfeeding or pregnant 18. Currently participating in active follow-up phase of another clinical study of an investigational drug or device 19. Active COVID-related infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments 20. Subject has other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures 21. Considered to be part of a vulnerable population (defined as individuals with mental disability, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention)